Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for controlling angiogenesis in animals

An angiogenesis, animal body technology, applied in cardiovascular system diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as difficult application, unstable materials, and toxicity

Inactive Publication Date: 2005-07-06
格里科基因系统公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, many materials that appear promising in vitro prove to be relatively ineffective when used in vivo
And many of these types of materials are unstable, toxic or difficult to apply

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for controlling angiogenesis in animals
  • Method for controlling angiogenesis in animals
  • Method for controlling angiogenesis in animals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention recognizes the role played by galectins in angiogenesis and provides therapeutic substances capable of advantageously interacting with galectins, thereby modulating or preventing the manifestations of angiogenesis-dependent diseases . More specifically, the present invention recognizes that certain carbohydrate materials can bind to or interact with galectins, thereby modulating the interaction of galectins with cellular structures and controlling angiogenesis.

[0024] Galectins comprise a family of proteins expressed by plant and animal cells that bind β-galactosidose sugars. These proteins are found on the cell surface, in the cytoplasm and in the extracellular fluid. Typically in the molecular weight range of 29-34 kd (kilodaltons), they have an affinity for β-galactoside-containing substances and have been found to play important roles in many biological processes. Galectin-1 and galectin-3 are special members of this family, and they have b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Use of therapeutic materials capable of interacting with cell surface galectins to control angiogenesis-dependent or angiogenesis-regulated disease states. Certain therapeutic materials comprise a polymeric backbone with pendant side chains terminated with sugars. The present invention discloses specific therapeutic materials in which the polymeric backbone is based on galacturonic acid and the side chains are terminated with arabinose or galactose.

Description

field of invention [0001] The present invention relates to methods and compositions for controlling angiogenesis in animals. More particularly the invention relates to materials and methods for the treatment of diseases in which angiogenesis is a causative factor. Most particularly, the invention relates to methods and materials for controlling angiogenesis using compounds capable of interacting with galectins. Background of the invention [0002] The medical scientific community has recognized angiogenesis as an important factor in the initiation and / or progression of a number of different disease states. The term "angiogenesis" as used herein refers to the formation and growth of new blood vessels into a tissue or organ. Under normal physiological conditions, angiogenesis occurs only in certain limited situations in humans and animals. For example, angiogenesis is commonly observed during wound healing, fetal and embryonic development, and formation of the corpus luteum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/00A61K45/00A61K31/715A61K31/732A61P9/00C08B37/00C08B37/06
CPCA61K31/00A61K31/715A61K31/732A61P9/00
Inventor Y·常V·萨萨克
Owner 格里科基因系统公司